CClinicalTrials.gg
Active, not recruitingNCT07617090CIVIUS2025PALUpdated Jun 1, 2026

Volumetric Visual Fields at Intermediate and Near Distances in Presbyopic Patients Using Occupational and General-Purpose Progressive Addition Lenses

An interventional study of OPAL PC assesment and OPAL Office assessment in Presbyopia, sponsored by University of Seville. Active, not recruiting at 1 site in Spain. Open to participants aged 52 Years to 67 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by University of Seville · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
52 Years to 67 Years
Sex
All
01

Study summary

This single-center, randomized, double-blind, crossover clinical trial aims to compare the volumetric visual fields provided by two occupational progressive addition lenses (OPLs) optimized for intermediate and near vision in presbyopic patients. The study evaluates Vimax Zoom 1.5 FWD 4 m and Vimax PC 1.5 FWD 4 m lenses and Vimax Fit FRM, all of them with plano distance power and a +2.00 D near addition, in order to determine differences in the extent of clear vision at multiple working distances.

Participants will undergo a comprehensive optometric examination including medical and ocular history, visual acuity assessment, accommodative amplitude measurement, autorefraction, interpupillary distance measurement, ocular motility evaluation, confrontation visual fields, Amsler grid testing, and binocular vision assessment. Visual field measurements will then be performed using both study lenses under standardized conditions. Subjects will be instructed to maintain a fixed head position while identifying optotypes located at distances of 4 m, 2 m, 1.33 m, 80 cm, 40 cm, and 25 cm. Both lenses will be tested in random order under masked conditions so that neither participants nor investigators know which lens design is being evaluated during each phase.

At least 23 presbyopic participants are expected to be enrolled. The study procedures are non-invasive and are anticipated to be completed in a single one-hour visit, although additional sessions may be scheduled if necessary. No significant risks are expected beyond possible transient visual fatigue associated with the duration of testing.

The primary objective is to determine which occupational progressive lens design provides a greater spatial volume of clear vision and wider horizontal and vertical visual fields at different intermediate and near distances. The findings may contribute to improving personalized recommendations of occupational lenses according to patients' visual demands and working distances.

02

Conditions studied

  • Presbyopia

Browse trials for

Keywords

  • Occupational progressive lenses
  • Presbyopia
  • Visual field depth
  • Visual field area
  • Visual acuity
03

Who can participate

Ages eligible
52 Years to 67 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Spherical ametropia for distance vision ≤ ±4.00 D and astigmatic ametropia ≤ 1.00 D.
  • Decimal VA ≥ 0.8, either uncorrected (UCVA) or corrected (BCVA) with monofocal contact lenses.
  • Patients with a nasopupillary distance (NPD) of 31 mm, with a tolerance of ±2 mm in each eye

Exclusion criteria

Exclusion Criteria:

  • Astigmatism greater than ±1.00 D.
  • Patients wearing progressive contact lenses.
  • Patients who have undergone cataract surgery or have monofocal or multifocal intraocular lenses.
  • Anisometropia greater than 2.50 D.
  • Decimal distance visual acuity \< 0.8 (UCVA or BCVA) with monofocal contact lenses.
  • Patients without normal ocular motility or with partial dysfunction of one or more ex-traocular muscles, or with restricted visual fields or scotomas.
  • Visual suppression in one eye between 4 m and 25 cm.
  • Strabismus or nystagmus.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    OPL designed for PC use

    VIMAX PC: Occupational progressive lenses designed to provide clear vision from 400 cm to 40 cm, with a wider visual field optimized for monitor-based environments with a depth of field between 60 and 80 cm. These lenses, designated L1, were custom ordered with neutral distance power and a near addition of +2.00 D, a vertex distance of 13 mm, pantoscopic tilt of 8°, wrap angle of 6°, working distance of 40 cm, inset of 2.5 mm in both eyes, and NPD of 31 mm in each eye.

    Device: OPAL PC assesment

  • Experimental
    OPL designed for office use

    VIMAX ZOOM: Occupational progressive lenses also designed to provide clear vision from 400 cm to 40 cm, but with a more homogeneous distribution of the visual field across office and home environments, with a depth of field between 40 and 400 cm. These lenses, designated L2, were also custom ordered with neutral distance power and a near addition of +2.00 D, vertex distance of 13 mm, pantoscopic tilt of 8°, wrap angle of 6°, working distance of 40 cm, inset of 2.5 mm in both eyes, and NPD of 31 mm in both eyes.

    Device: OPAL Office assessment

  • Active comparator
    PAL

    VIMAX FIT: Progressive additional lenses custom ordered with neutral distance power and a near addition of +2.00 D, vertex dis-tance of 13 mm, pantoscopic tilt of 8°, wrap angle of 6°, working distance of 40 cm, inset of 2.5 mm in both eyes, and NPD of 31 mm in both eyes.

    Device: PAL assesment

Interventions

  • DeviceOPAL PC assesment

    Fitting and positioning of the spectacles : participants were instructed to move only their eyes and to verbally identify the letters indicated by the optometrist. Measurement of clear vision limits: the horizontal and vertical boundaries of clear vision were recorded on a scaled results sheet, as defined by the participant using the optotype, at distances of 400, 200, 133, 80, 40, and 25 cm, in that order

  • DeviceOPAL Office assessment

    Fitting and positioning of the spectacles : participants were instructed to move only their eyes and to verbally identify the letters indicated by the optometrist. Measurement of clear vision limits: the horizontal and vertical boundaries of clear vision were recorded on a scaled results sheet, as defined by the participant using the optotype, at distances of 400, 200, 133, 80, 40, and 25 cm, in that order

  • DevicePAL assesment

    Fitting and positioning of the spectacles : participants were instructed to move only their eyes and to verbally identify the letters indicated by the optometrist. Measurement of clear vision limits: the horizontal and vertical boundaries of clear vision were recorded on a scaled results sheet, as defined by the participant using the optotype, at distances of 400, 200, 133, 80, 40, and 25 cm, in that order

05

What researchers measure

Primary outcomes

  1. Visual field volume

    It will consist of the volume defined by two parallel surfaces bounded by the visual fields perceived with clear horizontal and vertical vision by the patient between the distances of 4 m and 25 cm while wearing each pair of spectacles. The volume will be calculated using the Heronian formula for the volume of a quadrangular pyramidal frustum.

    Time frame: Immediately after the adjustment of the frame where the lenses were placed, an average of 30 minutes per patient.

Secondary outcomes

  1. Visual fields surface

    Calculation of the visual field surface areas defined by the patient with each lens type at distances of 4 m, 2 m, 1.33 m, 80 cm, 40 cm, and 25 cm. For this purpose, the areas corresponding to the visual field regions of the lens located between the fitting cross and the intermediate and near viewing zones were summed in a 1:2 proportion, respectively, for each measured distance.

    Time frame: Immediately after the adjustment of the frame where the lenses were placed, an average of 30 minutes per patient.

06

Study locations

1 site
  • Pharmacy school, University of Seville
    Seville, Sevilla 41012, Spain
07

References and documents

Study documents

  • Study protocol · Sep 20, 2025

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT07617090
Lead sponsor
University of Seville
Responsible party
José Manuel Serrano Morales (Optometry degree, Pharmacy degree and PhD in Molecular Biology, Biomedicine and Clinical Research, University of Seville) — Principal investigator
First posted
Jun 1, 2026
Start date
Sep 29, 2025
Primary completion
Nov 28, 2025
Completion
Sep 2026 (estimated)
Last update
Jun 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion